BAMBI and CHGA in Prion Diseases: Neuropathological Assessment and Potential Role as Disease Biomarkers.

Creutzfeldt-Jakob disease biomarkers bone morphogenetic protein and activin membrane-bound inhibitor chromogranin A neuroinflammation prion disease scrapie sheep transgenic mice

Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
02 05 2020
Historique:
received: 25 03 2020
revised: 25 04 2020
accepted: 29 04 2020
entrez: 7 5 2020
pubmed: 7 5 2020
medline: 7 4 2021
Statut: epublish

Résumé

Prion diseases affect both animals and humans. Research in the natural animal model of the disease could help in the understanding of neuropathological mechanisms and in the development of biomarkers for human pathologies. For this purpose, we studied the expression of 10 genes involved in prion propagation in vitro in the central nervous system of scrapie-infected sheep. Dysregulated genes (

Identifiants

pubmed: 32370154
pii: biom10050706
doi: 10.3390/biom10050706
pmc: PMC7277700
pii:
doi:

Substances chimiques

Bambi protein, mouse 0
Biomarkers 0
Chromogranin A 0
Membrane Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Gobierno de Aragón
ID : C012/2014 and C020/2014 and Order IIU/2023/2017
Pays : International
Organisme : European Social Fund
ID : C012/2014 and C020/2014 and Order IIU/2023/2017
Pays : International
Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España
ID : AGL2015-67945-P
Pays : International
Organisme : Ministerio de Ciencia e Innovación
ID : RTI2018-098711-B-I00
Pays : International
Organisme : European Regional Development Fund
ID : AGL2015-67945-P, RTI2018-098711-B-I00
Pays : International
Organisme : Gobierno de Aragón
ID : Grupo de Referencia LAGENBIO (A19-17R)
Pays : International
Organisme : European Social Fund
ID : Construyendo Europa desde Aragón: Grupo de Referencia LAGENBIO (A19-17R)
Pays : International
Organisme : Instituto de Salud Carlos III
ID : PI19/00144
Pays : International

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Références

Theriogenology. 2014 Nov;82(8):1094-101
pubmed: 25168722
Prog Mol Biol Transl Sci. 2017;150:409-431
pubmed: 28838672
Vet Res. 2009 Sep-Oct;40(5):42
pubmed: 19401142
Br Med Bull. 2003;66:99-108
pubmed: 14522852
Neuroscience. 2010 Sep 29;170(1):289-97
pubmed: 20600637
J Neural Transm (Vienna). 2011 May;118(5):727-35
pubmed: 21533607
Biochim Biophys Acta. 2013 Feb;1832(2):323-35
pubmed: 23168040
Ann Neurol. 2005 Aug;58(2):242-57
pubmed: 16049922
Neuroscience. 1992;46(1):1-8
pubmed: 1594095
N Engl J Med. 2003 Mar 20;348(12):1134-49
pubmed: 12646671
Gynecol Oncol. 2010 May;117(2):189-97
pubmed: 20189233
Nucleic Acids Res. 2009 Apr;37(6):e45
pubmed: 19237396
PLoS One. 2016 Jan 25;11(1):e0147727
pubmed: 26807844
J Comp Pathol. 2009 Aug-Oct;141(2-3):135-46
pubmed: 19515381
J Toxicol Environ Health A. 2011;74(2-4):110-26
pubmed: 21218340
Brain Res. 1994 Jan 21;634(2):339-44
pubmed: 8131084
PLoS One. 2011;6(5):e19909
pubmed: 21629698
Acta Neurol Scand. 2017 Oct;136(4):360-364
pubmed: 28185258
C R Biol. 2002 Jan;325(1):49-57
pubmed: 11862622
FEBS Lett. 1990 Apr 24;263(2):337-9
pubmed: 2110534
EMBO J. 2014 Jul 17;33(14):1527-47
pubmed: 24843046
Curr Genomics. 2012 Aug;13(5):369-78
pubmed: 23372423
Lab Invest. 2020 Jan;100(1):52-63
pubmed: 31477795
J Biol Chem. 1998 Jun 5;273(23):14339-46
pubmed: 9603942
Neuroscience. 1996 May;72(2):377-89
pubmed: 8737408
J Neurosci. 2010 Jan 27;30(4):1502-11
pubmed: 20107078
Sci Rep. 2019 Feb 13;9(1):1911
pubmed: 30760781
J Leukoc Biol. 2017 Jan;101(1):87-98
pubmed: 28049142
Ann Neurol. 1998 Jan;43(1):32-40
pubmed: 9450766
Anim Biotechnol. 2010;21(1):1-13
pubmed: 20024782
Nature. 1999 Sep 30;401(6752):480-5
pubmed: 10519551
J Comp Pathol. 1968 Jul;78(3):301-11
pubmed: 4970192
Sci Rep. 2016 Nov 25;6:37844
pubmed: 27886261
J Virol Methods. 2006 Jun;134(1-2):15-29
pubmed: 16406559
Neurosci Lett. 1994 Mar 28;170(1):13-6
pubmed: 8041489
Mol Neurobiol. 2018 Nov;55(11):8586-8591
pubmed: 29572672
Eur J Biochem. 1993 Oct 1;217(1):247-57
pubmed: 8223562
BMC Genomics. 2012 Aug 16;13:399
pubmed: 22897917
Vet Rec. 1967 Jan 7;80(1):2-9
pubmed: 4961994
Science. 1982 Apr 9;216(4542):136-44
pubmed: 6801762
J Biol Chem. 2009 Oct 30;284(44):30097-104
pubmed: 19758997
J Gen Virol. 2017 Feb;98(2):305-310
pubmed: 27959774
Neuroreport. 2003 Apr 15;14(5):755-8
pubmed: 12692477
Front Aging Neurosci. 2014 Aug 04;6:198
pubmed: 25136317
Endocr Connect. 2014 Apr 29;3(2):R45-54
pubmed: 24671122
J Mol Neurosci. 2017 Dec;63(3-4):308-319
pubmed: 28983846
J Neural Transm (Vienna). 2010 Aug;117(8):919-47
pubmed: 20632195

Auteurs

Óscar López-Pérez (Ó)

Laboratorio de Genética Bioquímica (LAGENBIO), Universidad de Zaragoza, Instituto Agroalimentario de Aragón-IA2, Instituto de Investigación Sanitaria Aragón-IISA, 50013 Zaragoza, Spain.
Centro de Encefalopatías y Enfermedades Transmisibles Emergentes (CEETE), Universidad de Zaragoza, Instituto Agroalimentario de Aragón-IA2, Instituto de Investigación Sanitaria Aragón-IISA, 50013 Zaragoza, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, 28029 Madrid, Spain.
Instituto de Investigación Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.

Marcos Bernal-Martín (M)

Laboratorio de Genética Bioquímica (LAGENBIO), Universidad de Zaragoza, Instituto Agroalimentario de Aragón-IA2, Instituto de Investigación Sanitaria Aragón-IISA, 50013 Zaragoza, Spain.

Adelaida Hernaiz (A)

Laboratorio de Genética Bioquímica (LAGENBIO), Universidad de Zaragoza, Instituto Agroalimentario de Aragón-IA2, Instituto de Investigación Sanitaria Aragón-IISA, 50013 Zaragoza, Spain.

Franc Llorens (F)

Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, 28029 Madrid, Spain.
Instituto de Investigación Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Department of Neurology, Clinical Dementia Center and National Reference Center for CJD Surveillance, University Medical School, 37075 Göttingen, Germany.

Marina Betancor (M)

Centro de Encefalopatías y Enfermedades Transmisibles Emergentes (CEETE), Universidad de Zaragoza, Instituto Agroalimentario de Aragón-IA2, Instituto de Investigación Sanitaria Aragón-IISA, 50013 Zaragoza, Spain.

Alicia Otero (A)

Centro de Encefalopatías y Enfermedades Transmisibles Emergentes (CEETE), Universidad de Zaragoza, Instituto Agroalimentario de Aragón-IA2, Instituto de Investigación Sanitaria Aragón-IISA, 50013 Zaragoza, Spain.
Department of Biological Sciences, Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, AB T6G 2R3, Canada.

Janne Markus Toivonen (JM)

Laboratorio de Genética Bioquímica (LAGENBIO), Universidad de Zaragoza, Instituto Agroalimentario de Aragón-IA2, Instituto de Investigación Sanitaria Aragón-IISA, 50013 Zaragoza, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, 28029 Madrid, Spain.

Pilar Zaragoza (P)

Laboratorio de Genética Bioquímica (LAGENBIO), Universidad de Zaragoza, Instituto Agroalimentario de Aragón-IA2, Instituto de Investigación Sanitaria Aragón-IISA, 50013 Zaragoza, Spain.

Inga Zerr (I)

Department of Neurology, Clinical Dementia Center and National Reference Center for CJD Surveillance, University Medical School, 37075 Göttingen, Germany.

Juan José Badiola (JJ)

Centro de Encefalopatías y Enfermedades Transmisibles Emergentes (CEETE), Universidad de Zaragoza, Instituto Agroalimentario de Aragón-IA2, Instituto de Investigación Sanitaria Aragón-IISA, 50013 Zaragoza, Spain.

Rosa Bolea (R)

Centro de Encefalopatías y Enfermedades Transmisibles Emergentes (CEETE), Universidad de Zaragoza, Instituto Agroalimentario de Aragón-IA2, Instituto de Investigación Sanitaria Aragón-IISA, 50013 Zaragoza, Spain.

Inmaculada Martín-Burriel (I)

Laboratorio de Genética Bioquímica (LAGENBIO), Universidad de Zaragoza, Instituto Agroalimentario de Aragón-IA2, Instituto de Investigación Sanitaria Aragón-IISA, 50013 Zaragoza, Spain.
Centro de Encefalopatías y Enfermedades Transmisibles Emergentes (CEETE), Universidad de Zaragoza, Instituto Agroalimentario de Aragón-IA2, Instituto de Investigación Sanitaria Aragón-IISA, 50013 Zaragoza, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, 28029 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH